Literature DB >> 17575677

Risk factors for non-adherence to directly observed treatment (DOT) in a rural tuberculosis unit, South India.

P G Gopi1, M Vasantha, M Muniyandi, V Chandrasekaran, R Balasubramanian, P R Narayanan.   

Abstract

OBJECTIVE: To identify risk factors for non-adherence of tuberculosis (TB) patients to DOT.
METHODS: Retrospective study of TB patients by logistic regression analysis to identify risk factors for non-adherence.
RESULTS: Of the 1666 patients interviewed, 1108 (67%) adhered and 558 (33%) did not adhere to DOT. Of 558 patients, the risk factors associated with non-adherence were illiteracy (39%), difficulty in accessing health facility (57%), and non-government DOT centre (43%).
CONCLUSION: Patients should be educated about tuberculosis and importance of DOT. All DOT centres, including Non-government DOT centres, should be made more accessible and patient-friendly.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17575677

Source DB:  PubMed          Journal:  Indian J Tuberc        ISSN: 0019-5707


  20 in total

1.  Smear Conversion, Treatment Outcomes and the Time of Default in Registered Tuberculosis Patients on RNTCP DOTS in Puducherry, Southern India.

Authors:  Kavita Vasudevan; Niranjana Jayakumar; Dhivyalakshmi Gnanasekaran
Journal:  J Clin Diagn Res       Date:  2014-10-20

2.  Risk factors for treatment default among re-treatment tuberculosis patients in India, 2006.

Authors:  Ugra Mohan Jha; Srinath Satyanarayana; Puneet K Dewan; Sarabjit Chadha; Fraser Wares; Suvanand Sahu; Devesh Gupta; L S Chauhan
Journal:  PLoS One       Date:  2010-01-25       Impact factor: 3.240

3.  Risk factors associated with default among new smear positive TB patients treated under DOTS in India.

Authors:  Sophia Vijay; Prahlad Kumar; Lakbir Singh Chauhan; Balasangameshwara Hanumanthappa Vollepore; Unnikrishnan Pallikkara Kizhakkethil; Sumathi Govinda Rao
Journal:  PLoS One       Date:  2010-04-06       Impact factor: 3.240

4.  Time of default in tuberculosis patients on directly observed treatment.

Authors:  Geeta S Pardeshi
Journal:  J Glob Infect Dis       Date:  2010-09

5.  Modeling the impact of early therapy for latent tuberculosis patients and its optimal control analysis.

Authors:  S Mushayabasa; C P Bhunu
Journal:  J Biol Phys       Date:  2013-08-23       Impact factor: 1.365

6.  Sputum completion and conversion rates after intensive phase of tuberculosis treatment: an assessment of the Rwandan control program.

Authors:  Felix R Kayigamba; Mirjam I Bakker; Veronicah Mugisha; Michel Gasana; Maarten F Schim van der Loeff
Journal:  BMC Res Notes       Date:  2012-07-16

7.  Factors that influence treatment adherence of tuberculosis patients living in Java, Indonesia.

Authors:  Bagoes Widjanarko; Michelle Gompelman; Maartje Dijkers; Marieke J van der Werf
Journal:  Patient Prefer Adherence       Date:  2009-11-03       Impact factor: 2.711

8.  TB treatment initiation and adherence in a South African community influenced more by perceptions than by knowledge of tuberculosis.

Authors:  Jane M Cramm; Harry J M Finkenflügel; Valerie Møller; Anna P Nieboer
Journal:  BMC Public Health       Date:  2010-02-17       Impact factor: 3.295

9.  Natural History and Factors Associated with Early and Delayed Mortality in HIV-Infected Patients Treated of Tuberculosis under Directly Observed Treatment Short-Course Strategy: A Prospective Cohort Study in India.

Authors:  Gerardo Alvarez-Uria; Praveen Kumar Naik; Raghavakalyan Pakam; Lakshminaryana Bachu; Manoranjan Midde
Journal:  Interdiscip Perspect Infect Dis       Date:  2012-12-18

10.  Understanding Nonadherence to Tuberculosis Medications in India Using Urine Drug Metabolite Testing: A Cohort Study.

Authors:  Ramnath Subbaraman; Beena E Thomas; J Vignesh Kumar; Kannan Thiruvengadam; Amit Khandewale; S Kokila; Maya Lubeck-Schricker; M Ranjith Kumar; Gunjan Rahul Gaurkhede; Apurva Shashikant Walgude; J Hephzibah Mercy; Jagannath Dattatraya Kumbhar; Misha Eliasziw; Kenneth H Mayer; Jessica E Haberer
Journal:  Open Forum Infect Dis       Date:  2021-05-05       Impact factor: 3.835

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.